Neomorph

aid: neomorph
name: Neomorph
description: Neomorph, Inc. is a venture-backed, clinical-stage biotechnology company headquartered at 5590 Morehouse Drive
  in San Diego, California, founded in 2020 to design molecular glue degraders — small molecules that bind an E3 ubiquitin
  ligase, reshape it into a new "neomorphic" surface, and recruit disease-causing proteins to the proteasome for destruction.
  The approach targets the roughly 85% of the human proteome considered undruggable by conventional small molecules because
  it needs no traditional binding pocket. Neomorph's platform reaches beyond cereblon to hundreds of E3 ligases and multiple
  proprietary degrons, which the company describes as the largest proprietary molecular glue target space in the field. Its
  lead programme, NEO-811, targets ARNT/HIF-1β in clear cell renal cell carcinoma and entered a Phase 1/2 trial in February
  2026; the rest of the pipeline spans undisclosed solid tumors plus partnered oncology/immunology, neurology and cardiometabolic/rare
  disease targets. The company closed a $109 million Series A in December 2020 and a $100 million Series B in April 2026,
  and runs multi-target discovery collaborations with Novo Nordisk (February 2024), Biogen (October 2024) and AbbVie (January
  2025). Philip Chamberlain, DPhil is CEO and Robert J. Hugin was appointed Chairman of the Board in May 2026. Neomorph runs
  no developer program and publishes no product API, developer portal, API reference, SDK or pricing. The only machine-readable
  surface reachable without credentials is the WordPress REST content API behind neomorph.com, catalogued here.
deliveryModel:
  model: saas
  open_source: false
  commercial: true
  callable_host: true
  label: Hosted service · you call their endpoint
  confidence: high
  source:
  - openapi
  - pricing
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: open
  trial: false
  try_now: false
  public: true
  gated: none
  gated_source:
  - onboarding
  label: Open access
  confidence: medium
  source:
  - authentication
  - rate-limits
  - security
  generated: '2026-11-02'
  method: derived
image: https://neomorph.com/wp-content/uploads/2026/03/OG-Neomorph.png
url: https://raw.githubusercontent.com/api-evangelist/neomorph/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enriched
specificationVersion: '0.23'
created: '2026-08-26'
modified: '2026-08-26'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Drug Discovery
- Targeted Protein Degradation
- MolecularGlue
- Oncology
- Immunology
- Rare Disease
- Clinical Trials
- Life Sciences
- content-api
tags_raw:
- Company
- biotechnology
- pharmaceuticals
- drug-discovery
- targeted-protein-degradation
- molecular-glue
- oncology
- immunology
- rare-disease
- clinical-trials
- life-sciences
- content-api
apis:
- aid: neomorph:neomorph-com-website-wordpress-rest
  name: Neomorph Website (WordPress REST)
  description: 'The public WordPress REST API (wp-json) of the Neomorph website at neomorph.com: the route index of the site''s
    content management system, catalogued as one site surface rather than as separate APIs.'
  baseURL: https://neomorph.com/wp-json
  tags:
  - WordPress
  x-surface: platform-generated
  properties:
  - type: Documentation
    url: https://neomorph.com/wp-json
  x-platform: wordpress
  x-platform-surface: rest
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://neomorph.com/
- type: About
  url: https://neomorph.com/about-us/
- type: Platform
  url: https://neomorph.com/platform/
- type: Pipeline
  url: https://neomorph.com/pipeline/
- type: Publications
  url: https://neomorph.com/publications/
- type: PatientResources
  url: https://neomorph.com/patients/
- type: News
  url: https://neomorph.com/news/
- type: BlogRSS
  url: https://neomorph.com/feed/
- type: Careers
  url: https://neomorph.com/careers/
- type: Contact
  url: https://neomorph.com/contact/
- type: PrivacyPolicy
  url: https://neomorph.com/privacy-policy/
- type: TermsOfService
  url: https://neomorph.com/terms-of-use/
- type: CookiePolicy
  url: https://neomorph.com/cookie-policy/
- type: Accessibility
  url: https://neomorph.com/accessibility-statement/
- type: LinkedIn
  url: https://www.linkedin.com/company/neomorph-llc/
- type: Twitter
  url: https://x.com/neomorphinc
- type: SecondaryMarket
  url: https://forgeglobal.com/neomorph_stock/
- type: Authentication
  url: authentication/neomorph-authentication.yml
- type: Conventions
  url: conventions/neomorph-conventions.yml
- type: Conformance
  url: conformance/neomorph-conformance.yml
- type: ErrorCatalog
  url: errors/neomorph-problem-types.yml
- type: Lifecycle
  url: lifecycle/neomorph-lifecycle.yml
- type: DataModel
  url: data-model/neomorph-data-model.yml
- type: RateLimits
  url: rate-limits/neomorph-rate-limits.yml
- type: Plans
  url: plans/neomorph-plans-pricing.yml
- type: DomainSecurity
  url: security/neomorph-domain-security.yml
- type: LLMsTxt
  url: llms/neomorph-llms.txt
- type: AgentSkill
  url: skills/_index.yml
x-enrichment:
  date: '2026-08-26'
  status: enriched
  artifacts_added: 28
  pass: local-v1